These three are the most commonly reported adverse reactions to Brintellix at greater than 5% and twice placebo

Which gender had the highest rates of sexual dysfunction when on Brintellix when
voluntarily reported :
When Asked ASEX

This product was approved by the FDA with 3 studies and has dose related adverse reactions including urinary hesitancy and erectile dysfunction

This forest product unlike Brintellix has a dosing recommendation to be taken with food, if not, the product may have a diminished effect.

These were the doses of Brintellix and the reference med, in the 2012 double blinded placebo study published in International Clinical Psychopharmacology , by Katona et al.

This is the amount of time needed from discontinuing a patient from an MAOI to Brintellix or the time it takes to reach steady state

These are the 5 categories of questions asked in the ASEX scale

This antidepressant shows no evidence of greater efficacy at doses higher than the starting dose, has a caution for hypertension, has a 12 % discontinuation rate compared to placebo and a half life of apx 11 hours.

Unlike Brintellix, this Forest Product has dosing adjustment for patients with renal impairments

This was the primary efficacy measure/ timeframe in the Katona Study

This percentage rate An adverse event was reported at both the 15 and 20 mg dose and the reason for discontinuation

The number of patients who reported sexual dysfunction in the Brintellix group versus the placebo group in the 24 to64 week of the long term study

This 2d6inhibitor antidepressant has nausea rates at 23% and a 53% remission rate in its long term study and a half life of apx 7 hours

Unlike 2 Brintellix studies where the mean MADRS change from placebo was -5.9, -5.7 -5.5 and-7.1; this forest product had a MADRS change of -3.2 and -2.5

This was the primary efficacy end points and results for Brintellix in the Katona study

This is the % of patients who continued to experience Nausea at the conclusion of the pooled 6 to 8 week studies at 10 and 20 mgs.

This percentage of patients reported sexual dysfunction in the Katona study; the same percentage compared to placebo but 6% less than the duloxteine group

This branded antidepressant is recommended to be titrated over 3 weeks to the recommended 40 mgs per day and has a half life of 25 hours and has common side effects like diarrhea, nausea vomiting and trouble sleeping

At its highest therapeutic dose This Forest product a
Had a mean change from baseline of 15 points , unlike Brintellix whose mean change from baseline across all doses was a17 point change

These were the three most common adverse events were reported during the treatment period for Brintellix in the Katona study

This was the maximum single dose and gender tested for Brintellix

In the Alvarez study, how many total patients had reported sexual dysfunction in the Brintellix doses compared to the 225 dose of venlafaxine

This antidepressant has reported nausea rates as high as 18%, dry mouth rates as high as 24% and headaches at 26% , with a mean half life of 21 hours and was previously marketed under another brand name Zyban

This Forest product with a complicated dosing regimen in increments of 12.5 mgs upto 100 mgs by day 7 , was approved in Europe as an antidepressant but in US for Fibromyalgia

These 2 tests were used in Katona Trial to evaluate cognitive effects, verbal learning and memory